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Abstract
Introduction: Empirical use of fluoroquinolones may delay the initiation of appropriate therapy for tuberculosis
(TB). This study aimed to evaluate the impact of empirical fluoroquinolone use on the survival of patients with
pulmonary TB that mimicked severe community-acquired pneumonia (CAP) requiring intensive care.
Methods: Patients aged >18 years with culture-confirmed pulmonary TB who presented as severe CAP and were
admitted to the ICU were divided into fluoroquinolone (FQ) and nonfluoroquinolone (non-FQ) groups based on
the type of empirical antibiotics used. Those patients with previous anti-TB treatment or those who died within 3
days of hospitalization were excluded. The primary end point was 100-day survival.
Results: Of the 77 patients identified, 43 (56%) were in the FQ group and 34 (44%) were in the non-FQ group. The
two groups had no statistically significant difference in co-morbidities (95% vs. 97%, P > 0.99) and Acute
Physiology and Chronic Health Evaluation (APACHE) II scores (21.2 ± 7.1 vs. 22.5 ± 7.5, P = 0.46) on ICU admission.
Overall, 91% and 82% of patients in the FQ and non-FQ groups, respectively, had sputum examinations for TB
within 1 week of admission (P = 0.46), and results were positive in 7% and 15% (P = 0.47), respectively. For both
groups, 29% received appropriate anti-TB therapy within 2 weeks after ICU admission. The 100-day mortality rate
was 40% and 68% for the FQ and non-FQ groups, respectively (P = 0.02). By Cox regression analysis, APACHE score
<20, no bacteremia during the ICU stay, and empirical fluoroquinolone use were independently associated with
survival.
Conclusion: Empirical use of fluoroquinolones may improve the survival of ICU patients admitted for pulmonary
TB mimicking severe CAP.
Introduction
Severe community-acquired pneumonia (CAP), defined
as pneumonia acquired in the community area that
rapidly progresses to require ICU admission, is a major
infectious cause of hospitalization and mortality [1]. In
patients presenting with severe CAP, fluoroquinolones
(FQs) have been recommended as first-line empiric anti-
biotic therapy due to their broad-spectrum antimicrobial
effect [2]. The use of FQs has been proven to reduce
the length of hospital stay and is more cost-effective
than using the combination therapy of b-lactams plus
macrolides [3,4].
In endemic areas of tuberculosis (TB), the clinical man-
ifestations of pulmonary TB are highly variable and may
even mimic CAP [5,6]. Although FQs have excellent in
vitro and in vivo bactericidal activity against Mycobacter-
ium tuberculosis [7-9], empirical use of FQ monotherapy
for CAP has raised concerns regarding delays in the
initiation of appropriate anti-TB therapy, an increase in
mortality and the emergence of drug resistance [10-13].
However, several other studies do not corroborate these
findings [14-18]. In different TB endemic areas, it is diffi-
cult to define the relationship between the duration of
FQ exposure and the development of resistance to FQ.
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Addressing the effects of different FQs on delays or resis-
tance is also difficult, which may explain the contradic-
tory results.
In patients with pulmonary TB requiring intensive
care, the mortality rate approaches 50% [19]. Among the
deaths, about 50% occur within 26 days and 75% within
75 days after ICU admission [20]. Previous studies have
demonstrated that the survival of patients with TB can
be significantly improved if anti-TB therapy is started
within 14 days of hospitalization [11,21,22]. Whether
empirical use of FQ in critically ill patients can improve
survival or can cause delays in the diagnosis of TB and
increase mortality remains unclear.
This retrospective study aimed to investigate the
impact of empirical FQ use on the survival of patients
with pulmonary TB manifesting as severe CAP requiring
intensive care, in a TB endemic area.
Materials and methods
Study subjects
This retrospective study was conducted at the National
Taiwan University Hospital, a tertiary-care referral cen-
ter in Taiwan, where the 2008 incidence and mortality
rate of TB was 62 and 3.3 per 100,000 population,
respectively [23]. The database of the mycobacteriology
laboratory and ICU records was searched to identify
TB patients between January 2005 and December 2010.
The inclusion criteria were age ³18 years, culture-con-
firmed pulmonary TB, radiographic findings suggestive
of severe CAP that rapidly progressed and required
intensive care within 1 week of hospitalization, and no
previous anti-TB therapy except FQs prior to ICU
admission.
CAP was defined as pneumonia that developed out-
side the hospital setting, with classic symptoms of fever,
cough and dyspnea, laboratory findings of leukocytosis,
leucopenia or elevated serum C-reactive protein, and
radiographic findings of pulmonary consolidation. The
first-line anti-TB agents included isoniazid, rifampin,
ethambutol, pyrazinamide, and streptomycin. Acid-fast
smears and mycobacterial cultures of sputum and other
respiratory specimens were performed as described pre-
viously [24]. Indications for ICU admission included
respiratory failure or septic shock.
The identified patients were divided into two groups:
patients who received empiric FQ therapy (that is, levo-
floxacin, moxifloxacin, and ciprofloxacin) before pulmon-
ary TB was confirmed by culture (FQ group); and those
who received antibiotics other than FQs (non-FQ group).
The hospital’s Research Ethics Committee approved the
study (NCT registration number 9561707008). Informed
consent was waived.
Data collection
All of the medical records for the enrolled patients were
reviewed. Respiratory symptoms were defined as cough,
dyspnea, and hemoptysis. Gastrointestinal symptoms
were defined as nausea, vomiting, gastrointestinal bleed-
ing, or diarrhea. Steroid use was defined as use of >10
mg prednisolone daily during hospitalization [25]. Chest
images were independently reviewed by two pulmonolo-
gists. If a discrepancy was noted between their interpre-
tations, the image was further reviewed by a third
pulmonologist who was blinded to the results.
Bacteremia in the ICU was defined as positive blood cul-
tures obtained during the ICU stay, with the exclusion of
contaminated culture results (for example, only one in two
sets of blood cultures that reported Bacillus or coagulase-
negative staphylococci). The Acute Physiology and Chronic
Health Evaluation (APACHE) II score and the Sequential
Organ Failure Assessment score within the first 24 hours
of ICU admission were used to evaluate disease severity
and organ dysfunction [26,27]. Patients who received
immunosuppressants, anti-cancer chemotherapy, radiation,
and steroids [25], or had another disease that was suffi-
ciently advanced to suppress resistance to infection (for
example, leukemia, lymphoma, or acquired immunodefi-
ciency syndrome), were defined as immunocompromised
hosts. The primary end point was 100-day survival.
Statistical analysis
Inter-group difference was calculated using the indepen-
dent-samples t test for continuous variables and the chi-
square test or Fisher’s exact test for categorical variables,
as appropriate. Time-to-event curves were generated by
the Kaplan-Meier method and compared using the log-
rank test. Cox proportional hazards regression analysis
was performed to identify prognostic factors for 100-day
survival after ICU admission. The potential factors
included age, sex, empirical FQ use, immunocompro-
mised status, APACHE score (³20 vs. <20) [28], Sequen-
tial Organ Failure Assessment score (³8 vs. <8) [29],
albumin level (<3 vs. ³3) [30], bacteremia during ICU
stay, performance of acid-fast smears and mycobacterial
cultures of respiratory specimens within 1 week of ICU
admission, grading of acid-fast smears, and initiation of
anti-TB therapy within 2 weeks of ICU admission. Signif-
icance levels for entry into the stepwise variable selection
procedure were set at 0.15. Two-sided P < 0.05 was con-
sidered significant. All statistical analyses were performed
using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA).
Results
Between January 2005 and December 2010, 1,928
patients with culture-confirmed pulmonary TB were
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identified. Among these, 184 patients (9.5%) were
admitted to the ICU during their hospital stay, including
77 (4.0%) who presented as severe CAP that resulted in
respiratory failure or septic shock, and were enrolled for
this study. Of the 107 patients who were excluded, 61
(33.2%) were suspected of having TB and received anti-
TB therapy before their ICU admission, 29 (15.8%) had
no airway symptoms on presentation, 13 (7.1%) had
been hospitalized for more than 1 week before the ICU
admission, three (1.6%) died within 3 days after the ICU
admission, and one (0.5%) had no sufficient medical
information.
Of the 77 patients presenting severe CAP, empirical
FQs were given to 43 patients before the date of diagno-
sis of culture-confirmed pulmonary TB (FQ group),
including 30 patients who received levofloxacin, seven
ciprofloxacin, and seven moxifloxacin (one patient
received more than one FQ during hospitalization). All
of these 43 patients took FQs for more than 3 days
(range, 3 to 155 days; mean duration FQ intake, 9.5
days). Of the seven patients who received ciprofloxacin,
the FQ was started when a diagnosis of nosocomial
infection was made more than 3 days after admission.
All patients in the FQ and non-FQ groups received
other b-lactam antibiotics before their ICU stay, includ-
ing amoxicillin/clavulanic acid in 11.6% and 14.7% (P =
0.74), respectively, ampicillin/sulbactam in 20.9% and
35.3% (P = 0.20), respectively, anti-pseudomonal antibio-
tics in 53.5% and 61.8% (P = 0.50), respectively, and
linezolid in 2.3% and 0% (P > 0.99), respectively.
All except one patient (98%) in the FQ group had
undergone investigations for other respiratory patho-
gens, which included urine antigen tests for Legionella,
serology tests for Mycoplasma pneumoniae, and nasal
swab for influenza. One patient tested positive for influ-
enza and another had concurrent pneumococcal pneu-
monia with bacteremia that caused respiratory failure.
In the non-FQ group, 62% had undergone studies for
other respiratory pathogens and only one tested positive
for Mycoplasma IgM.
Based on the clinical characteristics of the FQ and
non-FQ groups (Table 1), there were no statistically sig-
nificant differences in age, sex, co-morbidities, APACHE
score, Sequential Organ Failure Assessment score, and
radiographic findings between the two groups. The HIV
sero-status was available in 34 patients, including two in
the non-FQ group who were sero-positive for HIV. Of
the other 43 patients with unknown HIV sero-status,
none had AIDS-defining opportunistic illnesses except
TB during follow-up [31]. More patients in the FQ
group had fever as the initial symptom than in the non-
FQ group (63% vs. 35%, P = 0.02). Mean serum albumin
levels were <3 g/dl in both groups. Five patients in each
group did not need intubation on ICU admission and all
five in the FQ group survived, while two patients (40%)
in the non-FQ group died.
There were no statistically significant differences
between the two groups in the proportion of patients
who underwent sputum TB examination within 1 week
and those who started anti-TB therapy within 2 weeks
of ICU admission (Table 2). However, more patients in
the non-FQ group than in the FQ group died before
anti-TB therapy was started (27% vs. 9%, P = 0.05).
Among the 39 patients (91%) who received anti-TB
therapy in the FQ group, 16 continued to receive FQ for
>7 days together with anti-TB therapy.
For the FQ and non-FQ groups, the interval between
start of investigations for pulmonary TB and the start of
anti-TB therapy were 20.9 ± 14.7 and 16.8 ± 18.0 days
(P = 0.32), respectively. The interval between hospital
admission to initiation of anti-TB therapy was 24.1 ±
15.6 and 24.7 ± 17.2 days (P = 0.89), respectively. The
lengths of ICU stay (30.0 ± 20.5 days vs. 17.5 ± 17.9
days, P < 0.01) and hospitalization (71.2 ± 62.7 days vs.
38.4 ± 25.5 days, P < 0.01) were significantly longer in
the FQ group than in the non-FQ group.
Anti-TB susceptibility tests for the 77 isolates of M.
tuberculosis revealed resistance to streptomycin in two
cases and one case each to ethambutol co-resistance to
isoniazid and ethambutol, co-resistance to isoniazid and
streptomycin, and triple-resistance toisoniazid, rifampin
plus ethambutol. None of the isolates were resistant to
ofloxacin. Follow-up sputum samples were collected in
all of the 77 patients, and 26 (33.8%) were culture posi-
tive for M. tuberculosis, including 15 in the FQ group.
Of the 26 isolates, anti-TB susceptibility testing was
repeated in 10, including four in the FQ group. The sus-
ceptibility patterns of the 10 follow-up isolates were
identical to those of their corresponding initial isolates.
Forty patients (52%) died within 100 days of ICU
admission, including 17 (39.5%) in the FQ group and 23
(67.6%) in the non-FQ group. Twenty-three patients
(57.5%) died during their ICU stay, while 17 (42.5%)
died after their transfer out of the ICU. The cause of
death was pneumonia in 26 patients (65%) and hyper-
capnic respiratory failure, ischemic bowel disease, acute
respiratory distress syndrome with shock, sepsis with
profound shock, disseminated TB confirmed by bone
marrow and urine sample cultures, and multi-drug-
resistant Acinetobacter baumannii empyema in one
patient each. Another eight patients died after hospital
discharge. Their deaths were judged to be attributed to
TB by the Taiwan Center for Disease Control.
The survival patterns of patients in the FQ and non-FQ
groups are shown in Figure 1. By Cox regression analysis,
APACHE score ³20 (hazards ratio = 3.75; 95% confidence
interval = 1.34 to 10.44), bacteremia in the ICU (hazards
ratio = 3.88; 95% confidence interval = 1.64 to 9.19), and
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empiric use of FQ (hazards ratio = 0.36; 95% confidence
interval = 0.17 to 0.77) were independently associated
with 100-day survival (Table 3).
Discussion
In the present study, 4% of the patients with culture-
confirmed pulmonary TB in Taiwan presented with clin-
ical and radiographic manifestations similar to severe
CAP that required intensive care support. The interval
between ICU admissions and start of anti-TB treatment
was about 3 weeks on average. The 100-day mortality
for such patients was as high as 52% (40/77). While the
severity of pneumonia on presentation and bacteremia
during the ICU stay had an adverse effect on survival,
empirical use of FQs may improve survival.
The finding of a high mortality rate in TB patients
presenting as severe CAP requiring intensive care is
consistent with that of a previous study [32] - which
had similar characteristics of the study population,
including old age, presence of underlying diseases, mal-
nutrition, and lack of anti-TB treatment within 14 days
of the initial visit. The causes for such high mortality
rates may be delays in diagnosis and in the timely initia-
tion of appropriate anti-TB therapy. As shown in this
study, most of the patients were older people, with a
mean age of 72 years, and had multiple co-morbidities.
Consideration of other competing bacterial etiologies for
pneumonia may cause delays, on top of concerns
regarding the adverse effects of empirical initiation of
anti-TB therapy before conventional approaches to the
Table 1 Clinical characteristics of patients in the fluoroquinolone and nonfluoroquinolone groups on ICU admission
Fluoroquinolone (n = 43) Nonfluoroquinolone (n = 34) P value
Age (years) 72.9 ± 12.4 76.2 ± 14.5 0.28
Male 33 (77) 26 (77) 0.99
Underlying diseases 41 (95) 33 (97) >0.99
Diabetes mellitus 12 (28) 6 (18) 0.29
COPD 5 (12) 9 (27) 0.09
Malignancy 8 (19) 5 (15) 0.65
Autoimmune disease 2 (5) 1 (3) 0.7
Liver cirrhosis 2 (5) 0 (0)
HIV 0 (0) 2 (6)
Initial symptoms
Respiratory symptoms 40 (93) 32 (94) >0.99
Fever 27 (63) 12 (35) 0.02
Consciousness disturbance 11 (26) 4 (12) 0.13
APACHE score 21.2 ± 7.1 22.5 ± 7.5 0.46
Arterial pH 7.4 ± 0.1 7.4 ± 0.1 0.19
Serum sodium 136.6 ± 6.7 135.0 ± 8.5 0.35
Serum potassium 3.9 ± 0.8 4.1 ± 0.7 0.26
Serum creatinine 1.8 ± 1.7 1.9 ± 1.8 0.87
Hematocrit 32.5 ± 6.8 32.6 ± 5.6 0.93
Leukocyte count (103/μl) 13.9 ± 8.5 12.8 ± 7.2 0.53
FiO2 ³50% 32 (74) 20 (59) 0.22
Albumin (g/dl) 2.7 ± 0.5 2.8 ± 0.5 0.29
Bacteremia in ICUa 5 (12) 6 (18) >0.99
SOFA score 8.0 ± 3.6 7.3 ± 3.9 0.47
Radiographic findings
Bilateral involvement 34 (79) 27 (79) >0.99
Cavitation 3 (7) 0 (0) 0.25
Miliary 1 (2) 1 (3) >0.99
Pleural effusion 21 (49) 21 (62) 0.36
Smear-positive for acid-fast bacilli 3 (7) 5 (15) 0.47
Steroid use 21 (49) 19 (56) 0.65
Undergone bronchoscopy 5 (12) 5 (15) 0.95
Data presented as n (%) or mean ± standard deviation. APACHE, Acute Physiology and Chronic Health Evaluation score; COPD, chronic obstructive pulmonary
disease; FiO2, the fraction of inspired oxygen; SOFA, Sequential Organ Failure Assessment score.
aBlood culture was positive for Pseudomonas aeruginosa in two
patients, Acinetobacter baumannii in two patients, and for Proteus spp., Enterobacter spp., Escherichia coli, Klebsiella pneumoniae, Streptococcus pneumoniae,
Staphylococcus haemolyticus, Corynebacterium spp., Burkholderia cepacia, Candida parapsilosis, and Fusobacterium nucleatum in one patient each. Two patients had
more than one pathogen.
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Table 2 Treatment course and outcome in the fluoroquinolone and nonfluoroquinolone groups
Fluoroquinolone (n = 43) Nonfluoroquinolone (n = 34) P value
ICU admission to TB study (days) 1.7 ± 5.9 5.6 ± 15.1 0.13
TB study in the ICU within 1 week 39 (91) 28 (82) 0.46
Died before ATT was begun 4 (9) 9 (27) 0.05
Initiation of ATT in the ICU within 2 weeks 11 (29) 7 (29) >0.99
Length of ICU stay (days) 30.0 ± 20.5 17.5 ± 17.9 <0.01
Nonsurvivors in the ICU 27.0 ± 18.0 22.0 ± 25.0 0.27
Survivors in the ICU 31.0 ± 21.6 16.0 ± 14.0 0.03
Intubation period (days) 38.6 ± 61.5 19.5 ± 24.0 0.09
Nonsurvivors in the ICU 28.0 ± 18.35 25.0 ± 29.2 0.13
Survivors in the ICU 43.0 ± 71.5 16.9 ± 21.4 <0.01
Length of hospital stay(days) 71.2 ± 62.7 38.4 ± 25.5 <0.01
Nonsurvivors in the hospital 42.0 ± 28.0 37.0 ± 26.41 0.83
Survivors in the hospital 81.0 ± 63.3 40.0 ± 25.4 <0.01
100-day mortality rate 17 (40) 23 (68) 0.02
Data presented as n (%) or mean ± standard deviation. ATT, anti-tuberculosis treatment; TB, tuberculosis.
Figure 1 Kaplan-Meier 100-day survival curves for patients in the fluoroquinolone and non-fluoroquinolone groups .
The fluoroquinolone (FQ) and non-FQ groups were compared using the log-rank test.
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diagnosis of pulmonary TB are completed to provide
guidance.
FQs are broad-spectrum antimicrobial agents recom-
mended for patients with severe CAP requiring ICU
admission [2]. Despite concerns that empirical use of
FQs for severe CAP may be associated with delayed
diagnosis and treatment of pulmonary TB [11,33], the
findings in this study suggest that empirical use of FQs
may actually improve the prognosis of TB patients pre-
senting as severe CAP that require intensive care. Aside
from benefits of activity against common bacteria that
cause severe CAP in older people, FQs in this special
condition may also provide survival benefit by rapidly
reducing the mycobacterial load [34,35]. In this study,
65% of patients in the FQ group had sputum culture
conversion after FQ monotherapy. Although more pro-
spective studies with larger sample sizes are warranted
to confirm the findings here, the results suggest that the
delay in diagnosis of active pulmonary TB and the
timely initiation of anti-TB therapy may be prevented in
TB endemic areas if investigations for pulmonary TB
are routinely performed for patients with severe CAP.
b-Lactams such as amoxicillin/clavulanate may also
have antibacterial activity against M. tuberculosis [36]. A
population-based cohort study in Canada between 1997
and 2006 reported that previous treatments with any
antibiotics, not only FQ, are associated with delayed TB
diagnosis [37]. Use of b-lactams is probably not a con-
founding factor in the survival analysis, however,
because all of the patients in this study received b-lac-
tams on admission. There is no significant difference in
the proportion of patients who received b-lactam anti-
biotics. Moreover, there is no significant difference in
the intervals from the time of pulmonary TB investiga-
tion or from ICU admission to the start of anti-TB ther-
apy between the FQ and non-FQ groups.
The findings of APACHE score ≥20 and bacteremia
during the ICU stay as poor prognostic factors are con-
sistent with those of previous studies [28,38]. Nearly
80% of patients belong to the older age group, which
may preclude identifying age ≥70 years as an indepen-
dent risk factor in this study. In contrast to previous
reports [11,21,22], initiation of standard anti-TB therapy
within 2 weeks of ICU admission has no consistent sig-
nificant impact on survival. This is probably due to the
small case number in this study and due to less than
one-third of the patients being treated early after admis-
sion to the ICU.
This study has several limitations such that interpreta-
tion of the results should be made with caution. First,
Table 3 Independent factors associated with 100-day survival, by multivariate Cox proportional hazards regression
analysis
Patients (n) Mortality within
100 days, n (%)
Median survival of
fatal cases (days)
P value Hazards ratio 95% confidence
interval
Age
≥70 60 34 (56.7) 50 0.32 1.75 0.58 to 5.31
<70 17 6 (35.3) 16
APACHE score
≥20 52 33 (63.5) 36 0.01 3.75 1.34 to 10.44
<20 25 7 (28.0) 100
SOFA score
≥8 35 19 (54.3) 44 0.21 1.63 0.76 to 3.49
<8 41 20 (48.8) 100
Empiric antibiotic
Fluoroquinolone 43 17 (39.5) 46 <0.01 0.36 0.17 to 0.77
Nonfluoroquinolone 34 23 (67.6) 60
Bacteremia in the ICU
Yes 11 9 (81.8) 46 <0.01 3.88 1.64 to 9.19
No 66 31 (47.0) 49
TB study in the ICU within 1 week
Yes 67 36 (53.7) 47.5 0.22 1.99 0.66 to 5.99
No 10 4 (40.0) 48.5
Initiation of ATT in ICU within 2 weeks
Yes 18 10 (55.6) 68.5 0.53 1.38 0.50 to 3.84
No 44 17 (38.6) 40
APACHE, Acute Physiology and Chronic Health Evaluation score; ATT, anti-tuberculosis treatment; SOFA, Sequential Organ Failure Assessment score; TB,
tuberculosis.
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this is a retrospective study and biases and missing data
are unavoidable. For example, HIV sero-status and the
cause of death are unknown in 43 and eight patients in
the FQ and non-FQ groups, respectively. However, this
may not be such a serious concern because HIV preva-
lence in the general population (<0.1%) and in patients
with TB (<1%) remains low in Taiwan [39]. None of the
patients with unknown HIV sero-status developed AIDS-
defining illness during follow-up. Second, the study was
conducted on older patients with clinical presentations of
severe CAP in a medical center. The results may not be
applicable to all patients with pulmonary TB that do not
require critical care. Third, conventional diagnostic tests
for TB (acid-fast smears and culture) are used in this
study and, as such, appropriate anti-TB therapy was not
initiated in the patients until 3 weeks into their hospital
stay. The impact of molecular technology on facilitating
rapid TB diagnosis in this clinical setting warrants further
studies. Fourth, the case number of pulmonary TB
mimicking severe CAP remains small so the number of
M. tuberculosis isolates submitted for drug susceptibility
tests obtained during FQ treatment is also small. The risk
for emergence of acquired resistance to FQs cannot thus
be adequately evaluated. Lastly, despite efforts to adjust
for the confounding effects of disease severity and organ
dysfunction, the decision of choosing empiric therapy in
the face of severe CAP may be based on other factors
(for example, drug allergy, toxicity profile, and previous
medication history) that are not included in the statistical
model.
Conclusion
Empirical use of FQs may improve survival of patients
admitted to the ICU for pulmonary TB mimicking
severe CAP.
Key messages
• Four percent of the patients with culture-confirmed
pulmonary TB in Taiwan present as severe CAP requir-
ing intensive care.
• The mortality rate is high in TB patients presenting
as severe CAP requiring intensive care.
• Empirical use of FQs may improve survival for TB
patients presenting as severe CAP requiring intensive care.
Abbreviations
APACHE: Acute Physiology and Chronic Health Evaluation; CAP: community-
acquired pneumonia; FQ: fluoroquinolone; TB: tuberculosis.
Author details
1Department of Traumatology, National Taiwan University Hospital and
National Taiwan University College of Medicine, No. 7, Chung Shan S. Road,
Zhongzheng District, Taipei City 10002, Taiwan. 2Department of Internal
Medicine, National Taiwan University Hospital and National Taiwan University
College of Medicine, No. 7, Chung Shan S. Road, Zhongzheng District, Taipei
City 10002, Taiwan.
Authors’ contributions
Y-TT reviewed the medical records, analyzed and interpreted the data, and
drafted the manuscript. C-CH, Y-CC, C-CS, and C-CH, analyzed and
interpreted the data, and drafted the manuscript. C-FH reviewed the medical
records. J-YW designed and oversaw the study, analyzed and interpreted the
data, and revised the manuscript. All authors read and approved the
manuscript for publication.
Competing interests
The authors declare that they have no competing interests.
Received: 8 July 2012 Revised: 10 September 2012
Accepted: 22 October 2012 Published: 25 October 2012
References
1. Marti C, Garin N, Grosgurin O, Poncet A, Combescure C, Carballo S,
Perrier A: Prediction of severe community-acquired pneumonia: a
systematic review and meta-analysis. Crit Care 2012, 16:R141.
2. Mandell LA, Wunderink RG, Anzueto A, Bartlett JG, Campbell GD, Dean NC,
Dowell SF, File TM Jr, Musher DM, Niederman MS, Torres A, Whitney CG:
Infectious Diseases Society of America/American Thoracic Society
consensus guidelines on the management of community-acquired
pneumonia in adults. Clin Infect Dis 2007, 44:S27-S72.
3. Frei CR, Labreche MJ, Attridge RT: Fluoroquinolones in community-
acquired pneumonia: guide to selection and appropriate use. Drugs
2011, 71:757-770.
4. Watkins RR, Lemonovich TL: Diagnosis and management of community-
acquired pneumonia in adults. Am Fam Physician 2011, 83:1299-1306.
5. Scott JA, Hall AJ, Muyodi C, Lowe B, Ross M, Chohan B, Mandaliya K,
Getambu E, Gleeson F, Drobniewski F, Marsh K: Aetiology, outcome, and
risk factors for mortality among adults with acute pneumonia in Kenya.
Lancet 2000, 355:1225-1230.
6. Liam CK, Pang YK, Poosparajah S: Pulmonary tuberculosis presenting as
community-acquired pneumonia. Respirology 2006, 11:786-792.
7. Cremades R, Rodriquez JC, Garcia-Pachón E, Galiana A, Ruiz-García M,
López P, Royo G: Comparison of the bactericidal activity of various
fluoroquinolones against Mycobacterium tuberculosis in an in vitro
experimental model. J Antimicrob Chemother 2011, 66:2281-2283.
8. Yew WW, Chan CK, Chau CH, Tam CM, Leung CC, Wong PC, Lee J:
Outcome of patients with multi-drug-resistant pulmonary tuberculosis
treated with ofloxacin/levofloxacin-containing regimens. Chest 2000,
117:744-751.
9. Ziganshina LE, Squire SB: Fluoroquinolones for treating tuberculosis.
Cochrane Database Syst Rev 2008, 1:CD004795.
10. Dooley KE, Golub J, Goes FS, Merz WG, Sterling TR: Empiric treatment of
community-acquired pneumonia with fluoroquinolones, and delays in
the treatment of tuberculosis. Clin Infect Dis 2002, 34:1607-112.
11. Wang JY, Hsueh PR, Jan IS, Lee LN, Liaw YS, Yang PC, Luh KT: Empirical
treatment with a fluoroquinolone delays the treatment for tuberculosis
and is associated with a poor prognosis in endemic areas. Thorax 2006,
61:903-908.
12. Devasia RA, Blackman A, Gebretsadik T, Griffin M, Shintani A, May C,
Smith T, Hooper N, Maruri F, Warkentin J, Mitchel E, Sterling TR:
Fluoroquinolone resistance in Mycobacterium tuberculosis: the effect of
duration and timing of fluoroquinolone exposure. Am J Respir Crit Care
Med 2009, 180:365-370.
13. Long R, Chong H, Hoeppner V, Shanmuganathan H, Kowalewska-
Grochowska K, Shandro C, Manfreda J, Senthilselvan A, Elzainy A, Marrie T:
Empirical treatment of community-acquired pneumonia and the
development of fluoroquinolone-resistant tuberculosis. Clin Infect Dis
2009, 48:1354-1360.
14. Golub JE, Bur S, Cronin WA, Gange S, Sterling TR, Oden B, Baruch N,
Comstock GW, Chaisson RE: Impact of empiric antibiotics and chest
radiograph on delays in the diagnosis of tuberculosis. Int J Tuberc Lung
Dis 2005, 9:392-397.
15. Yoon YS, Lee HJ, Yoon HI, Yoo CG, Kim YW, Han SK, Shim YS, Yim JJ:
Impact of fluoroquinolones on the diagnosis of pulmonary tuberculosis
initially treated as bacterial pneumonia. Int J Tuberc Lung Dis 2005,
9:1215-1219.
16. van den Boogaard J, Semvua HH, van Ingen J, Mwaigwisya S, van der
Laan T, van Soolingen D, Kibiki GS, Boeree MJ, Aarnoutse RE: Low rate of
Tseng et al. Critical Care 2012, 16:R207
http://ccforum.com/content/16/5/R207
Page 7 of 8
fluoroquinolone resistance in Mycobacterium tuberculosis isolates from
northern Tanzania. J Antimicrob Chemother 2011, 66:1810-1814.
17. Park IN, Hong SB, Oh YM, Lim CM, Lee SD, Lew WJ, Koh Y, Kim WS, Kim DS,
Kim WD, Shim TS: Impact of short-term exposure to fluoroquinolones on
ofloxacin resistance in HIV-negative patients with tuberculosis. Int J
Tuberc Lung Dis 2007, 11:319-324.
18. Wang JY, Lee LN, Lai HC, Wang SK, Jan IS, Yu CJ, Hsueh PR, Yang PC:
Fluoroquinolone resistance in Mycobacterium tuberculosis isolates:
associated genetic mutations and relationship to antimicrobial exposure.
J Antimicrob Chemother 2007, 59:860-865.
19. Wang JY, Lee LN, Hsueh PR: Factors changing the manifestation of
pulmonary tuberculosis. Int J Tuberc Lung Dis 2005, 9:777-783.
20. Lee PL, Jerng JS, Chang YL, Chen CF, Hsueh PR, Yu CJ, Yang PC, Luh KT:
Patient mortality of active pulmonary tuberculosis requiring mechanical
ventilation. Eur Respir J 2003, 22:141-147.
21. Wang JY, Hsueh PR, Jan IS, Lee LN, Liaw YS, Yang PC, Luh KT: The effect of
smoking on tuberculosis: different patterns and poorer outcomes. Int J
Tuberc Lung Dis 2007, 11:143-149.
22. Wang JY, Hsueh PR, Wang SK, Jan IS, Lee LN, Liaw YS, Yang PC, Luh KT:
Disseminated tuberculosis: a 10-year experience in a medical center.
Medicine (Baltimore) 2007, 86:39-46.
23. Center for Disease Control of Taiwan: Statistics of Communicable Diseases
and Surveillance Report in Taiwan Area, 2009 Taipei, Taiwan: Center for
Disease Control; 2009 [http://www2.cdc.gov.tw/public/Data/
912311651471.pdf].
24. Wang JY, Lee LN, Chou CS, Huang CY, Wang SK, Lai HC, Hsueh PR, Luh KT:
Performance assessment of a nested-PCR assay (the RAPID BAP-MTB)
and the BD ProbeTec ET system for detection of Mycobacterium
tuberculosis in clinical specimens. J Clin Microbiol 2004, 42:4599-4603.
25. Stuck AE, Minder CE, Frey FJ: Risk of infectious complications in patients
taking glucocorticosteroids. Rev Infect Dis 1989, 11:954-963.
26. Knaus WA, Draper EA, Wagner DP, Zimmerman JE: APACHE II: a severity of
disease classification system. Crit Care Med 1985, 13:818-829.
27. Vincent JL, Moreno R, Takala J, Willatts S, De Mendonça A, Bruining H,
Reinhart CK, Suter PM, Thijs LG: The SOFA (Sepsis-related Organ Failure
Assessment) score to describe organ dysfunction/failure. On behalf of
the Working Group on Sepsis-Related Problems of the European Society
of Intensive Care Medicine. Intensive Care Med 1996, 22:707-710.
28. Matic I, Titlic M, Dikanovic M, Jurjevic M, Jukic I, Tonkic A: Effects of
APACHE II score on mechanical ventilation; prediction and outcome.
Acta Anaesthesiol Belg 2007, 58:177-183.
29. Ferreira FL, Bota DP, Bross A, Mélot C, Vincent JL: Serial evaluation of the
SOFA score to predict outcome in critically ill patients. JAMA 2001,
286:1754-1758.
30. Kim HJ, Lee CH, Shin S, Lee JH, Kim YW, Chung HS, Han SK, Shim YS,
Kim DK: The impact of nutritional deficit on mortality of in-patients with
pulmonary tuberculosis. Int J Tuberc Lung Dis 2010, 14:79-85.
31. Centers for Disease Control and Prevention. [http://www.cdc.gov/mmwr/
preview/mmwrhtml/rr5710a2.htm].
32. Erbes R, Oettel K, Raffenberg M, Mauch H, Schmidt-loanas M, Lode H:
Characteristics and outcome of patients with active pulmonary
tuberculosis requiring intensive care. Eur Respir J 2006, 27:1223-1228.
33. Ginsburg AS, Hooper N, Parrish N, Dooley KE, Dorman SE, Booth J, Diener-
West M, Merz WG, Bishai WR, Sterling TR: Fluoroquinolone resistance in
patients with newly diagnosed tuberculosis. Clin Infect Dis 2003,
37:1448-1452.
34. Johnson JL, Hadad DJ, Boom WH, Daley CL, Peloquin CA, Eisenach KD,
Jankus DD, Debanne SM, Charlebois ED, Maciel E, Palaci M, Dietze R: Early
and extended early bactericidal activity of levofloxacin, gatifloxacin in
pulmonary tuberculosis. Int J Tuberc Lung Dis 2006, 10:605-612.
35. Pletz MWR, De Roux A, Roth A, Neumann KH, Mauch H, Lode H: Early
bactericidal activity of moxifloxacin in treatment of pulmonary
tuberculosis: a prospective, randomized study. Antimicrob Agents
Chemother 2004, 48:780-782.
36. Dinçer I, Ergin A, Kocagöz T: The vitro efficacy of beta-lactam and beta-
lactamase inhibitors against multi-drug resistant clinical strains of
Mycobacterium tuberculosis. Int J Antimicrob Agents 2004, 23:408-411.
37. Wang M, Fitzgerald JM, Richardson K, Marra CA, Cook VJ, Hajek J,
Elwood RK, Bowie WR, Marra F: Is the delay in diagnosis of pulmonary
tuberculosis related to exposure to fluoroquinolones or any antibiotic?
Int Tuberc Lung Dis 2011, 15:1062-1068.
38. Nasa P, Juneja D, Singh O, Dang R, Arora V, Saxena S: Incidence of
bacteremia at the time of ICU admission and its impact on outcome.
Indian J Anaesth 2011, 55:594-598.
39. Yang CH, Huang YF, Wang KF, Chan PC, Chen KJ: Trend of HIV prevalence
in Tuberculosis patients in Taiwan, 2001-2008 Poster Presentation at
40th Union World Conference on Lung Health, December 2009 Cancun,
Maxico..
doi:10.1186/cc11839
Cite this article as: Tseng et al.: Empirical use of fluoroquinolones
improves the survival of critically ill patients with tuberculosis
mimicking severe pneumonia. Critical Care 2012 16:R207.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Tseng et al. Critical Care 2012, 16:R207
http://ccforum.com/content/16/5/R207
Page 8 of 8
